Skip to main content
    E

    Emergent Biosolutions Inc (EBS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $7.18
    +0.27 (+3.91%)

    Market Cap: $354.30M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    -26.91%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.39
    Range$-0.41 - $-0.37
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.35-211.8%
    60d ago$0.35-211.8%
    30d ago$0.35-211.8%
    7d ago$-0.41+4.5%
    Current$-0.39
    Revenue Consensus
    $123M
    Range$118M - $129M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.89
    Range$0.89 - $0.89
    2 analysts
    Revenue Consensus
    $196M
    Range$184M - $205M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.89---
    Sep 26EST
    		-$-0.39---
    Jun 26
    Reported Aug 5
    		$0.60$0.11+445.45%Beat+275.0%
    Mar 26
    Reported Apr 30
    		$0.21$-0.25+184.00%Beat-70.4%
    Dec 25
    Reported Feb 26
    		$-0.43$0.42-201.18%Miss+25.5%
    Sep 25
    Reported Oct 29
    		$1.06$-0.12+983.33%Beat-22.6%
    Jun 25
    Reported Aug 6
    		$0.16N/A+132.65%Beat+106.9%
    Mar 25
    Reported May 7
    		$0.71$0.44+61.36%Beat+20.3%
    Dec 24
    Reported Mar 3
    		$-0.58$-0.50-16.50%Miss+25.0%
    Sep 24
    Reported Nov 6
    		$1.37$0.14+878.57%Beat+127.0%
    Jun 24
    Reported Aug 6
    		$-2.32$-0.97-139.18%Miss-118.9%
    Mar 24
    Reported May 1
    		$0.59$-0.83+171.08%Beat+118.6%
    Dec 23
    Reported Mar 6
    		$-0.77$-0.19-305.26%Miss-148.4%
    Sep 23
    Reported Nov 7
    		$-5.08$-0.54-840.74%Miss-300.0%
    Jun 23
    Reported Aug 8
    		$-1.06$-0.62-70.97%Miss-23.3%
    Mar 23
    Reported May 9
    		$-3.17$-1.34-136.57%Miss-1861.1%
    Dec 22
    Reported Feb 27
    		$-0.31$0.04-875.00%Miss-106.9%
    Sep 22
    Reported Nov 8
    		$-1.27$-0.13-876.92%Miss-252.8%
    Jun 22
    Reported Aug 1
    		$-0.86$0.40-315.00%Miss-360.6%
    Mar 22
    Reported Apr 28
    		$0.18$0.13+38.46%Beat-88.2%
    Dec 21
    Reported Feb 24
    		$4.50$4.27+5.39%Beat+22.6%
    Sep 21
    Reported Nov 4
    		$-0.36N/A-115.79%Miss-116.4%
    Jun 21
    Reported Jul 29
    		$0.33N/A-78.85%Miss-83.3%
    Mar 21
    Reported Apr 29
    		$1.53$1.17+30.77%Beat+15200.0%
    Dec 20
    Reported Feb 18
    		$3.67$3.19+15.05%Beat+133.8%
    Sep 20
    Reported Nov 5
    		$2.19$2.15+1.86%Beat+81.0%
    Jun 20
    Reported Jul 30
    		$1.98$0.66+200.00%Beat+1550.0%
    Mar 20
    Reported Apr 30
    		$0.01$0.01+0.00%Beat+107.7%
    Dec 19
    Reported Feb 20
    		$1.57$1.73-9.25%Miss+109.3%
    Sep 19
    Reported Nov 6
    		$1.21$0.90+34.44%Beat+120.0%
    Jun 19
    Reported Aug 1
    		$0.12$0.18-33.33%Miss-88.8%
    Mar 19
    Reported May 2
    		$-0.13$0.18-172.22%Miss-333.3%
    Dec 18
    Reported Feb 21
    		$0.75$0.65+15.38%Beat+1.4%
    Sep 18
    Reported Nov 1
    		$0.55$0.61-9.84%Miss-24.7%
    Jun 18
    Reported Aug 2
    		$1.07$0.93+15.05%Beat+723.1%
    Mar 18
    Reported May 3
    		$-0.03N/A-117.65%Miss-110.3%
    Dec 17
    Reported Feb 22
    		$0.74$0.70+5.71%Beat+0.0%
    Sep 17
    Reported Nov 2
    		$0.73$0.41+78.05%Beat-
    Jun 17
    Reported Aug 3
    		$0.13$0.26-50.00%Miss-
    Mar 17
    Reported May 4
    		$0.29$0.30-3.33%Miss-
    Dec 16
    Reported Feb 23
    		$0.74$0.61+21.31%Beat-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio4.99EV/EBITDA20.06x
    Price/FCF4.31xFCF Yield23.19%
    Profitability
    Profit Margin-23.00%Operating Margin28.30%
    ROE-40.30%ROIC-6.76%
    Financial Health
    Debt/Equity1.70xInterest Coverage2.16x
    Current Ratio5.42xQuick Ratio2.95x
    Trading Statistics
    Beta2.29Avg Volume1.10M
    52-Week High$14.0652-Week Low$4.36

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.94
    SMA 20$6.83
    SMA 50$6.07
    SMA 200$8.36
    EMA 10$6.94
    EMA 20$6.79
    EMA 50$6.66
    EMA 200$7.64

    MACD

    Line: 0.19Signal: 0.18Hist: 0.00

    ADX

    ADX: 20.6+DI: 29.0-DI: 16.4

    Aroon & PSAR

    Aroon Up68.0
    Aroon DownN/A
    PSAR$6.45

    Bollinger Bands

    Upper Band$7.31
    Lower Band$6.35
    %B Position1403%(Upper)
    Band Width0.87

    RSI (14-Day)

    Neutral
    59.1

    Momentum Oscillators

    Stoch %K53.9
    Stoch %D51.9
    Williams %R-33.3
    ROC (10d)12.7%
    Momentum0.81
    CCI (20d)102.1
    MFI (14d)54.2

    Volatility Measures

    ATR (14d)$0.38(5.3%)
    StdDev (20d)0.24
    Hist Vol67.5%(High)

    Volume Flow

    VWAP$7.08
    OBV-15.5M
    AD Line-15.8M
    CMF (20d)-0.133

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.6x
    VWMA (20d)$6.86

    Pivot Points

    R3$7.31
    R2$7.19
    R1$7.05
    Pivot Point$6.93
    S1$6.79
    S2$6.67
    S3$6.53

    Advanced Oscillators

    TSI13.25
    Ultimate Osc50.9
    KST165.44

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$234.30M$156.10M$148.70M$231.10M$140.90M$222.20M$194.70M$293.80M$254.70M$300.40M$-755,700,000$519.30M
    Cost of Revenue$97.10M$72.00M$84.90M$85.90M$66.90M$88.50M$118.00M$122.60M$296.10M$144.60M$-182,300,000$353.60M
    Gross Profit$137.20M$84.10M$63.80M$145.20M$74.00M$133.70M$76.70M$171.20M$-41,400,000$155.80M$-573,400,000$165.70M
    Operating Expenses$262.30M$73.60M$91.70M$68.70M$72.40M$83.80M$86.20M$106.70M$162.10M$116.00M$-495,500,000$335.80M
    R&D$9.20M$10.50M$12.10M$13.50M$12.50M$15.10M$9.10M$13.80M$32.70M$15.10M$29.40M$15.30M
    SG&A$44.60M$46.60M$51.10M$38.90M$43.70M$52.40M$60.80M$76.60M$85.90M$84.70M$-541,100,000$86.00M
    Operating Income$-125,100,000$10.50M$-27,900,000$76.50M$1.60M$49.90M$-9,500,000$64.50M$-203,500,000$39.80M$-43,800,000$-242,100,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$30.50M$11.00M$26.90M$15.20M$14.70M$14.70M$14.20M$8.30M$23.60M$24.30M$10.70M$23.80M
    Income Before Tax$-166,300,000$13.40M$-50,700,000$57.60M$-16,800,000$92.70M$-27,600,000$142.40M$-269,800,000$12.10M$-54,500,000$-265,900,000
    Income Tax Expense$13.90M$6.60M$3.90M$6.40M$-4,800,000$24.70M$3.70M$27.60M$13.30M$3.10M$-5,000,000$-2,500,000
    Net Income$-180,200,000$6.80M$-54,600,000$51.20M$-12,000,000$68.00M$-31,300,000$114.80M$-283,100,000$9.00M$-49,500,000$-263,400,000
    EBITDA$-110,200,000$49.70M$2.30M$98.70M$23.80M$135.10M$14.80M$170.40M$-212,700,000$71.20M$-42,700,000$-212,500,000
    EBIT$-135,800,000$24.40M$-23,800,000$72.80M$-2,100,000$107.40M$-13,400,000$150.70M$-246,200,000$36.40M$-78,000,000$-246,200,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EBS

    Government Contracts

    Gov Obligations (TTM)
    $277.58M
    Gov Obligations / Revenue
    41.0%
    Obligations YoY
    13.9%
    Active Awards
    11
    New Awards (TTM)
    3
    Avg Remaining Term
    6.6 mo

    Top agency: Department of Health and Human Services at 92.2% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    W911SR26FA005Department of DefenseDepartment of the Army$21.53MJan 4, 2026
    75N98026P00379Department of Health and Human ServicesNational Institutes of Health$11232Apr 27, 2026
    75D30126P20965Department of Health and Human ServicesCenters for Disease Control and Prevention$2825Apr 10, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Emergent BioSolutions stock rises 3.91 percent with USD 368.1 million value

    Emergent BioSolutions (EBS) stock rose by 3.91 percent on the NYSE, closing at USD 7.18 with a market capitalization of USD 368.1 million. HC Wainwright has set a USD 10.00 price target for the stock...

    ad-hoc-news.de•10/15/26•Bullish

    Emergent BioSolutions stock rises 3.91 percent with USD 368.1 million value

    Emergent BioSolutions (EBS) stock rose 3.91% on the NYSE to EUR 6.43, with a market capitalization of USD 368.1 million. HC Wainwright has set a target price of USD 10.00 for the stock. The company is set to discuss its...

    ad-hoc-news.de•10/15/26•Neutral

    Emergent BioSolutions director DeGolyer sells $126k in shares

    Emergent BioSolutions director Donald W. DeGolyer sold 17,800 shares of the company's common stock for $126,202 to cover tax obligations from vested restricted stock units. Despite the insider sale and the stock...

    Investing.com•10/8/26•Somewhat-Bearish

    Form 4 Emergent Biosolutions Inc For: 7 October By Investing.com

    This article announces the filing of a Form 4 for Emergent Biosolutions Inc. on October 7. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change...

    Investing.com Canada•10/7/26•Neutral

    Director Donald DeGolyer proposes selling 17,800 Emergent BioSolutions (NYSE: EBS) shares.

    Emergent BioSolutions director Donald DeGolyer has filed a Form 144 proposing to sell 17,800 shares of common stock, with an aggregate market value of $126,120.12. The shares are restricted stock acquired on October 2...

    Stock Titan•10/7/26•Neutral

    EBS Valuation and Fair Value

    P/E
    5.0x
    Forward P/E
    23.0x
    EV/EBITDA
    20.1x
    P/FCF
    4.3x
    PEG
    0.4x
    P/B
    1.1x
    See GNG's fair value

    EBS Profitability: Margins, ROIC and FCF

    Gross margin
    55.9%
    Operating margin
    28.3%
    Net margin
    -23.0%
    ROIC
    -6.8%
    ROE
    -40.3%
    FCF margin
    11.2%
    FCF yield
    23.2%

    EBS Competitors

    CompanyTicker
    Fennec Pharmaceuticals IncFENC
    Kyverna Therapeutics, Inc. Common StockKYTX
    Galectin Therapeutics IncGALT
    Embecta CorpEMBC
    Wellgistics Health, Inc. Common StockWGRX
    Opus Genetics, Inc.IRD
    Viemed Healthcare IncVMD
    Orchestra BioMed Holdings Inc.OBIO

    Sector: Healthcare

    EBS Analyst Ratings

    Consensus
    Hold
    Analysts
    3
    Strong Buy
    0
    Buy
    2
    Hold
    0
    Sell
    0
    Strong Sell
    1

    EBS Bull Case vs Bear Case

    Bull case

    • EBS beat EPS estimates in 75.0% of its last 8 reported quarters.
    • EBS grew quarterly revenue 66.3% year over year.

    Bear case

    • EBS has a -23.0% net profit margin.
    • 33.3% of EBS's analyst ratings are Sell or Strong Sell.

    EBS Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    308.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.39
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    EBS Dividend

    Forward yield
    0.0%
    Payout ratio
    0.0%

    Frequently Asked Questions About EBS

    Does EBS pay dividends?

    Emergent Biosolutions Inc (EBS) has a dividend payment track record. See the EBS dividend history page for its current payment status, TTM yield, and recorded payments.

    What is EBS's P/E ratio?

    Emergent Biosolutions Inc has a price-to-earnings (P/E) ratio of 4.99.

    What is EBS's market cap?

    Emergent Biosolutions Inc (EBS) has a market capitalization of $354.30M with a current stock price of $7.18.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In